From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

December 5, 2025

Countdown to Event

00

Days

00

Hours

00

Mins

00

Secs

Overview:

Lambert-Eaton myasthenic syndrome (LEMS) is a rare, frequently under-recognized paraneoplastic neurologic disorder that may occur in patients with small cell lung cancer (SCLC). Overlapping features with myasthenia gravis, chemotherapy-induced neuropathy, or deconditioning often delay diagnosis, leading to significant morbidity, functional decline, and missed opportunities to identify SCLC earlier.

This interactive, hybrid satellite symposium will be presented in conjunction with the 2025 IASLC North America Conference on Lung Cancer in Chicago, Illinois. Using a case-based format, our expert faculty will highlight hallmark clinical clues, outline evidence-based diagnostic pathways, and provide strategies for optimizing care with available therapies and multidisciplinary coordination. By addressing real-world challenges in recognition and management, the session aims to equip clinicians with actionable tools to improve outcomes for patients with SCLC and LEMS.


Learning Objectives:

Upon completion of this activity, participants will be able to:

  • Identify distinguishing clinical features of paraneoplastic LEMS that warrant further workup
  • Apply a guideline-concordant diagnostic pathway for LEMS that incorporates findings from physical exam, electrodiagnostic studies, antibody testing, and imaging
  • Initiate therapy for paraneoplastic LEMS with appropriate consideration for titration and monitoring
  • Define best practices for multidisciplinary fast-track pathways with defined roles, referral SLAs, and EMG access targets